PP405, the gel that aims to wake dormant hair follicles: what the AWAKEN trial means for Malaysians

Every few months a new hair loss headline goes viral, and in October 2026 it was PP405: an experimental gel described as able to "wake up" sleeping hair follicles. Screenshots of the news travel quickly through Malaysian WhatsApp groups, and questions follow just as fast. Is it available yet? Is it better than minoxidil? Should I wait for it instead of starting treatment now?

This guide explains what PP405 is, the biology it targets, what the early trial data actually show and what they do not, how the new AWAKEN trial is designed, and what all of this means in practical terms for someone losing hair in Malaysia today. It is general information, not personal medical advice.

The short answer

• PP405 is an investigational topical gel, not an approved medicine. No regulator anywhere has approved it, so it cannot be legally prescribed or bought in Malaysia¹.
• It targets the hair follicle's stem cells, not hormones. It is designed to reactivate dormant hair follicle stem cells by acting on a metabolic switch, rather than lowering DHT the way finasteride does¹².
• The first human trial was small and short. The Phase 2a study enrolled 78 men and women, used the gel once daily for four weeks and met its primary goal, which was safety³.
• Efficacy signals are early. Reports of increased density came from exploratory analyses, including a subgroup of men with more advanced loss, and had not appeared as a peer-reviewed paper at the time of writing³.
• The real test has just started. AWAKEN, a randomised, placebo-controlled Phase 2/3 trial of about 600 men in the United States and Canada, dosed its first patient in October 2026¹⁴.
• Do not wait for it. Proven options such as minoxidil and finasteride work best when started early, and the hair they protect today is the hair any future treatment would have to work with⁵⁶.

Why "dormant" follicles matter

To understand PP405, it helps to understand how a follicle grows a hair in the first place. Each hair follicle is a small organ that cycles through phases: a long growth phase (anagen), a short transition phase (catagen) and a resting phase (telogen), after which the old hair is shed and a new cycle should begin⁷. On the scalp, the growth phase normally lasts years, which is why scalp hair can grow long.

Every new growth phase starts with stem cells. These live in a region of the follicle called the bulge, and they stay quiet for much of the cycle. When the right signals arrive, a small group of them switches on, divides and builds a new hair shaft. Then they return to rest⁷.

In androgenetic alopecia, the common inherited pattern of hair loss in men and women, DHT acting on genetically sensitive follicles causes them to shrink gradually, a process called miniaturisation⁸. Over successive cycles, the growth phase shortens, the hairs become thinner and shorter, and the resting phase grows longer. Eventually some follicles sit in an extended resting state, producing little or no visible hair. For more background on the hormone side, see DHT and hair loss.

An important observation from research is that even in thinning areas, many follicles and their stem cells are still present. The problem is less that the stem cells have vanished and more that they are not being activated properly. This is the gap that PP405 is designed to address.

The science behind PP405: a metabolic switch

Most hair loss medicines work on the hormone pathway or on blood flow and growth signals around the follicle. PP405 takes a different route. Its developer, Pelage Pharmaceuticals, describes it as a non-invasive topical small molecule that targets "a unique metabolic switch that regulates hair follicle stem cell activation"¹.

The best-known published research on this switch comes from a team at the University of California, Los Angeles, published in Nature Cell Biology in 2017². Working in mice, the researchers found that:

• Hair follicle stem cells rely heavily on glycolysis, a way of using glucose, and produce more lactate than other skin cells.
• Lactate production appears critical for activation. When the researchers deleted the gene for lactate dehydrogenase (the enzyme that makes lactate) in these stem cells, the cells failed to activate.
• Boosting lactate sped things up. Deleting the mitochondrial pyruvate carrier, which normally pulls pyruvate into the cell's mitochondria, pushed the cells toward making lactate and accelerated activation and the hair cycle.
• Small molecules applied to the skin could trigger the hair cycle in mice by raising lactate production².

In plain terms, the stem cells seem to need a particular way of burning fuel before they can switch on, and nudging their metabolism in that direction may help restart a stalled cycle. Pelage says PP405 is supported by more than ten years of bench research into this mechanism, but it has not published the drug's exact structure in a way that allows a direct comparison with the compounds used in the mouse study¹. Mouse hair cycles also differ a great deal from human scalp hair, so mouse results cannot be assumed to translate.

What PP405 is not

Because the story is new and exciting, it is often misreported. A few clarifications help:

• It is not a hormone blocker. It does not lower DHT, so it does not share finasteride's or dutasteride's hormonal side-effect profile. The flip side is that it does not address the hormonal driver of pattern loss either.
• It is not a stem cell injection or transplant. It acts on the stem cells already in your follicles. For more on cell-based approaches, see stem cell therapy for hair and hair cloning and future treatments.
• It is not a shampoo, serum or supplement. It is a medicine under development, tested at a defined concentration in controlled trials.
• It is not available. It has no approval from the US Food and Drug Administration, Malaysia's National Pharmaceutical Regulatory Agency (NPRA) or any other authority.

What the trials have shown so far

Phase 2a: safety first, early signals second

The Phase 2a study enrolled 78 men and women with androgenetic alopecia, who applied PP405 or a placebo gel once daily for four weeks and were followed afterwards³. According to the company:

• The primary endpoint, safety, was met. The gel was well tolerated, no PP405 was detected in the bloodstream and no systemic adverse events were reported¹.
• Exploratory efficacy findings were encouraging. In a subgroup of men with more advanced hair loss, 31% of those on PP405 had more than a 20% increase in hair density at week 8, compared with 0% on placebo³.
• New hair from previously empty follicles was reported, which the company presents as early evidence of follicle reactivation¹.

These are genuinely interesting results, but they deserve careful reading. The study was small, the treatment period was only four weeks, the density finding came from a subgroup analysis rather than the main pre-specified outcome, and press releases are written by the company developing the drug. At the time of writing, the full dataset had not appeared as a peer-reviewed journal paper. Early-phase results in hair loss, as in other fields, sometimes fail to hold up in larger trials.

Phase 2/3 AWAKEN: the real test

AWAKEN is designed to answer the efficacy question properly. According to its registry entry and the company announcement⁴¹:

• Design: randomised, double-blind and placebo-controlled, with PP405 0.05% topical gel compared against a vehicle gel.
• Participants: about 600 adult men with Norwood-Hamilton type IV or V pattern hair loss, in the United States and Canada.
• Main outcome: change in non-vellus target area hair count at the crown at week 24, with a 52-week safety extension.
• Timeline: the study started in September 2026, the first patient was dosed in October 2026, primary completion is listed for December 2027 and full completion for June 2028.

A separate Phase 2 trial in women is planned to begin by the end of 2026¹. Women have fewer medical options for pattern hair loss, so a non-hormonal approach would be meaningful if it proves effective. For current options, see male pattern baldness treatment and the related guides on women's hair loss.

Step by step: from trial to a Malaysian pharmacy shelf

For anyone hoping to use PP405, it helps to see the path it must travel:

1. AWAKEN completes and reports results. The earliest listed primary completion is December 2027⁴. Results are usually announced some months after data collection ends.
2. Further trials may be needed. Regulators often expect more than one large trial, plus long-term safety data, before approval.
3. Approval in a first market. The company would need to file with regulators such as the US Food and Drug Administration, whose review takes additional time.
4. Malaysian registration. A medicine approved abroad is not automatically legal here. It must be registered with the NPRA before it can be sold in Malaysia.
5. Pricing and access. Only after that would price, prescription rules and availability through clinics and pharmacies become known.

Each step can be delayed or end the programme. No honest timeline for availability in Malaysia exists today, and anyone who quotes one is guessing.

How PP405 compares with today's options

The table below sets PP405 beside treatments for pattern hair loss that are available now. Evidence levels are summarised from systematic reviews and guidelines cited in this article.

For a broader ranking of approaches, see hair growth methods ranked by evidence.

Pros, cons and risks

Potential advantages if PP405 succeeds:

• A non-hormonal mechanism that could suit people who cannot or will not take DHT blockers.
• A topical gel with no detectable blood levels in early testing, which may mean fewer body-wide side effects¹.
• A possible option for women, if the planned women's trial is positive.
• A mechanism that might combine with existing treatments, although this has not been tested.

Current limitations and unknowns:

• Efficacy in humans has not been confirmed in a large controlled trial.
• Long-term safety beyond a year is unknown.
• It is unclear how much benefit would last after stopping.
• It does not address DHT, so ongoing miniaturisation may still need other treatment.
• It is not expected to help areas with no remaining follicles, such as long-standing smooth bald skin.

Risks right now: the biggest practical risk for Malaysians is not PP405 itself but imitations. Online sellers sometimes market "research chemicals", grey-market gels or products using the names of drugs still in trials. These are unregulated, their contents are unknown, and they may irritate the scalp or contain undeclared ingredients. Applying an unknown chemical to inflamed or broken skin can also cause contact dermatitis.

Typical timelines to keep in mind

• Hair cycle: any treatment that changes the growth cycle takes months to show; visible change after a single month is unusual⁷.
• Existing treatments: minoxidil and finasteride usually need 6 to 12 months before a fair assessment¹².
• PP405 trial results: primary completion for AWAKEN is listed for December 2027⁴.
• Availability in Malaysia: unknown, and dependent on approvals that have not yet been sought.

The Malaysian context

Pattern hair loss is common in Malaysia across Malay, Chinese, Indian and other communities, in both men and women. Several practical points apply here:

• Check registration. Before buying any hair loss medicine, check that it is registered with the NPRA. Registered products carry a MAL registration number on the pack.
• Beware of social media claims. Ads that mention "stem cell activation", "PP405 technology" or "follicle reactivation" for products sold today are borrowing the language of a trial drug. They are not PP405.
• Heat and humidity matter for topicals. In a humid climate, a sweaty or oily scalp can affect how a topical sits on the skin. Applying to a clean, dry scalp and following product directions helps.
• Where to go. For a diagnosis, start with a general practitioner or a dermatologist at a government hospital or private clinic. Hair and scalp centres can help with assessment, photos and maintenance, but prescription medicines should be overseen by a doctor.
• Costs. There is no price for PP405 because it is not sold anywhere. Costs for available treatments vary by product and provider, so ask for a written quote before committing.

Common myths

"PP405 brings back hair on any bald head." No trial has shown this. Hair needs living follicles, and areas that have been completely smooth for years may have few left.

"It is already sold overseas, so I can order it." It is not approved in any country. Products claiming to be PP405 are not the trial medicine.

"If something better is coming, there is no point starting treatment now." The opposite is true. Follicles lost to years of miniaturisation may be harder for any future treatment to rescue. Protecting hair now keeps future options open.

"Natural stem cell activators do the same thing." Shampoos, serums and supplements that use stem cell language have not been tested the way PP405 is being tested. See hair loss treatments with weak evidence.

"Non-hormonal means no side effects." Every active medicine can cause side effects. Early safety results are encouraging but involved a small number of people for a short time.

A practical checklist

• [ ] Get a proper diagnosis: confirm whether it is pattern hair loss, shedding or another cause⁶.
• [ ] Take baseline photos in the same light every month.
• [ ] Discuss proven treatments such as minoxidil and finasteride with a doctor.
• [ ] Do not stop a treatment that is working while waiting for new drugs.
• [ ] Ignore any seller offering PP405 or "the same ingredient" today.
• [ ] Check the MAL number for any hair loss medicine bought in Malaysia.
• [ ] Follow AWAKEN updates through ClinicalTrials.gov rather than social media⁴.
• [ ] Review progress after 6 to 12 months, not weeks.

The bottom line

PP405 is one of the more scientifically interesting ideas in hair loss research: rather than only slowing loss, it aims to restart follicles that have gone quiet. The early safety results are reassuring, and the efficacy hints are worth watching. But a four-week trial in 78 people is a beginning, not a verdict. The 600-man AWAKEN trial will give much clearer answers, and those are not expected before late 2027 at the earliest. In the meantime, the best way to keep future options open is to protect the hair and follicles you have now with treatments that already have strong evidence, such as topical finasteride and minoxidil, chosen with a doctor.

Frequently asked questions

Can I buy PP405 in Malaysia?

No. PP405 is an investigational medicine that is not approved by any regulator, including Malaysia's National Pharmaceutical Regulatory Agency. Anything sold online as PP405 is not the trial product and should be avoided.

When might PP405 become available?

Nobody can say yet. The AWAKEN trial lists its primary completion as December 2027 and full completion as June 2028. Regulatory review would follow only if results are positive, and Malaysian registration would be a separate step after that.

Is PP405 a hormone blocker like finasteride?

No. It is described as a non-hormonal topical small molecule that targets a metabolic switch in hair follicle stem cells, rather than blocking DHT.

Did PP405 work in the Phase 2a trial?

The trial met its primary goal, which was safety. Signs of increased density were exploratory, came partly from a subgroup analysis, and the full data had not appeared as a peer-reviewed paper at the time of writing.

Can it bring back hair on a completely bald, shiny scalp?

That has not been shown. Hair needs living follicles. Areas that have been smooth and shiny for many years may have few follicles left, and no trial has tested PP405 there.

Is PP405 for women too?

The Phase 2a study included men and women, but AWAKEN is men only. The company says a separate Phase 2 trial in women is planned to start by the end of 2026.

Should I stop minoxidil or finasteride while I wait?

No. Stopping a treatment that is working usually means losing the hair it was protecting over the following months. Any change should be discussed with a doctor.

Can I join the AWAKEN trial from Malaysia?

AWAKEN is recruiting in the United States and Canada only. Trial listings on ClinicalTrials.gov show current locations and eligibility.

Educational content. Not medical advice.